In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback